Importantly, we show for the first time that BCL-XL overexpression protects human β-cells without compromising insulin release, which sets the stage for the use of β-cell-specific BCL-XL overexpression as a potential therapeutic strategy in order to prevent β-cell loss during diabetes development. Here, INS is linked to diabetes mellitus.